Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus LEVORA 0 15 30 21.
BALZIVA-28 vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive